823
Participants
Start Date
October 31, 2007
Primary Completion Date
July 31, 2009
Study Completion Date
January 31, 2010
peginesatide
"Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
Epoetin alfa or Epoetin beta
"Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
Research Facility, Sofia
Research Facilities (2), Sofia
Research Facility, Sofia
Research Facility, Sofia
Research Facility, Plovdiv
Research Facility, Plovdiv
Research Facility, Pazardzhik
Research Facility, Veliko Tarnovo
Research Facility, Pleven
Research Facility, Rousse
Research Facility, Burgas
Research Facility, Varna
Research Facility, The Bronx
Research Facility, Brooklyn
Research Facility, Flushing
Research Facility, Ciudad Real
Research Facility, Erie
Research Facility, Philadelphia
Research Facility, Rockville
Research Facility, Fairfax
Research Facility, Como
Research Facility, Hamburg
Research Facility, Lecco
Research Facility, Cremona
Research Facility, Madrid
Research Facilities (2), Bremen
Research Facility, Asheville
Research Facility, Madrid
Research Facility, Orangeburg
Research Facility, Bordeaux
Research Facility, Pinecrest
Research Facility, Miami
Research Facility, Lauderdale Lakes
Research Facility, Montpellier
Research Facility, Santander
Research Facility, Brookhaven
Research Facility, Louisville
Research Facility, Modena
Research Facility, Toledo
Research Facility, Detroit
Research Facility, Detroit
Research Facility, Vannes
Research Facility, Prato
Research Facility, Hines
Research Facility, Flossmoor
Research Facility, Franfurt
Research Facility, Kaiserslautern
Research Facility, Pine Bluff
Research Facility, McGehee
Research Facility, Hot Springs
Research Facility, Oklahoma City
Research Facility, Arlington
Research Facility, Houston
Research Facility, San Antonio
Research Facility, Westminster
Research Facility, Amiens
Research Facility, Phoenix
Research Facility, Los Angeles
Research Facility, Los Angeles
Research Facility, Los Angeles
Research Facility, Whittier
Research Facility, Glendale
Research Facility, Riverside
Research Facility, Simi Valley
Research Facility, Bakersfield
Research Facility, Yuba City
Research Facility, Iași
Research Facility, Springfield
Research Facility, Providence
Research Facility, Ciechanów
Research Facility, Katowice
Research Facility, Pabianice
Research Facility, Włocławek
Research Facility, Bucharest
Research Facility, Bucharest
Research Facility, Alicante
Research Facility, Barcelona
Research Facility, Barcelona
Research Facility, Barcelona
Research Facility, Carshalton
Research Facility, London
Research Facility, London
Research Facility, London
Research Facility, Swansea